Physician profile
Alexander Wong
NPI 1992792402
$10,006.39
in general payments reported to CMS, 2019-2025
61 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,944 · 2020: $1,040 · 2021: $1,343 · 2022: $1,155 · 2023: $1,688 · 2024: $1,580 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892 · Education: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.74 |
| Education | $633.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,070.60 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $710.16 | 2021-2025 | Xtandi, Xospata, Padcev |
| Novartis Pharmaceuticals Corporation | $707.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $643.10 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $559.63 | 2019-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $494.11 | 2019-2025 | Tagrisso, Enhertu |
| Janssen Biotech, INC. | $488.32 | 2021-2025 | Erleada, Balversa |
| Celgene Corporation | $407.72 | 2019-2025 | Opdualag, Opdivo, Pomalyst |
| Lilly USA, LLC | $406.90 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $360.01 | 2019-2025 | |
| Pfizer INC. | $346.74 | 2019-2025 | |
| Mckesson Specialty Care Distribution, LLC | $265.86 | 2019 | |
| Daiichi Sankyo INC. | $257.17 | 2021-2025 | Enhertu |
| Genzyme Corporation | $213.39 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $202.89 | 2019-2024 | Ultomiris, Soliris |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $196.37 | 2019-2023 | |
| Seagen INC. | $174.95 | 2019-2023 | Adcetris |
| Glaxosmithkline, LLC. | $169.24 | 2021-2024 | Ojjaara, Shingrix |
| Rigel Pharmaceuticals, INC. | $164.53 | 2019-2024 | Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $141.41 | 2020-2025 | Xermelo, Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $133.80 | 2019-2025 | Fruzaqla |
| Emd Serono, INC. | $130.82 | 2020-2025 | Bavencio |
| Gilead Sciences, INC. | $122.03 | 2019-2024 | Trodelvy |
| Janssen Pharmaceuticals, INC | $114.99 | 2019-2024 | Xarelto |
| Pharmaessentia USA Corporation | $114.23 | 2023-2024 | Besremi |
| Abbvie INC. | $107.26 | 2022-2025 | Venclexta |
| Spectrum Pharmaceuticals INC. | $95.13 | 2024 | Rolvedon |
| Genentech USA, INC. | $87.32 | 2019 | |
| Eisai INC. | $77.27 | 2024-2025 | |
| Mylan Institutional INC. | $75.77 | 2019-2022 | |
| Puma Biotechnology, INC. | $74.78 | 2019-2024 | |
| Organon LLC | $69.39 | 2021-2022 | |
| Caris Mpi, INC. | $60.74 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $55.83 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $53.81 | 2021-2025 | Libtayo |
| Amneal Pharmaceuticals LLC | $53.42 | 2023-2024 | Neulasta, Avastin, Neupogen |
| Kyowa Kirin, INC. | $51.47 | 2019-2020 | |
| Tempus Ai, INC | $46.51 | 2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $42.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.51 | 2019-2021 | |
| Dova Pharmaceuticals | $32.40 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $28.83 | 2025 | Empaveli |
| Sobi, INC | $28.29 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $22.82 | 2020 | |
| Tesaro, INC. | $22.73 | 2019 | |
| Sumitomo Pharma America, INC. | $22.10 | 2023 | Orgovyx |
| Beone Medicines USA, INC. | $21.87 | 2025 | Brukinsa |
| Beigene USA, INC. | $21.29 | 2023 | Brukinsa |
| Shield Therapeutics INC | $20.78 | 2023 | Accrufer |
| Ferring Pharmaceuticals INC. | $20.35 | 2020 | |
| Epizyme, INC. | $20.19 | 2021 | |
| Stemline Therapeutics INC. | $17.93 | 2023 | Orserdu |
| Jazz Pharmaceuticals INC. | $16.83 | 2019 | |
| Coherus Oncology, INC. | $16.03 | 2023 | |
| Inari Medical, INC. | $13.95 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pharmacosmos Therapeutics INC. | $13.73 | 2024 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $13.03 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Abbott Laboratories | $11.43 | 2021 | |
| Heron Therapeutics, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.